No Detail Found!

Effects of Goserellin on Serum VEGF, Anti- Endometrial Antibody and Sex Hormone Levels in Patients with Endometriosis

Author(s)
Yugang Meng Department of Gynecology Division, The First Afiliated Hospital of Guangxi Medical University, Nanning, 530021, China
Xiting Yan Department of Gynecology Division, The Second Afiliated Hospital of Guangxi Medical University,Nanning, 530007,China
Haiying Liang Department of Gynecology Division, Wuming Hospital of Guangxi Medical University, Wuming School of Clinical Medicine of Guangxi Medical University,Nanning, 530199,China
Abstract
The objective of this study was to explore the effect of goserellin on the levels of serum vascular endothelial growth factor (VEGF), anti-endometrial antibody (EMAb) and sex hormone in patients with endometriosis. Participants in the study, 92 patients with endometriosis admitted from June 2016 to May 2017 to our hospital, randomly were divided into control group and study group (46 cases in each group). The control group was given routine treatment such as medroxyprogesterone acetate tablet, and the study group was given injection of goserellin on the basis of the control group. The changes of serum VEGF, EMAb, CA125 and sex hormones (FSH, LH, E2, P) were compared before and after treatment. Adverse reactions were recorded during the treatment The occurrence and recurrence were followed up for 1 year. After treatment, the total effective rate of the study group was 95.65%, which was significantly higher than the control group of 80.43% (P <0.05). After treatment, the VEGF level in the study group was significantly lower than the control group, and the EMAb, CA125 levels, and EMAb positive rates were significantly higher In the control group, the difference was statistically significant (P <0.05); after treatment, the levels of FSH, LH, E2, and P in the study group were significantly lower than those in the control group (P <0.05); there was no statistically significant difference in the incidence of adverse reactions between the two groups; After a 1-year follow-up, the relapse rate in the study group was 8.69%, which was significantly lower than the control group’s 52.17%. It was concluded that Goserellin has a definite clinical effect in the treatment of endometriosis. It can significantly reduce the levels of VEGF, EMAb and CA125 in serum, regulate the level of sex hormone, inhibit the growth of endometriosis, reduce the recurrence rate, and have a high safety.
Publication Details
Page(s) 2033-2037
Published Journal: Pakistan Journal of Zoology, Volume: 56, Issue: 5, Year: 2024

Request the full text from PASTIC

Keywords
Endometriosis, Vascular endothelial growth factor, Sex hormone, Antiendometrial antibody, Goserellin
0

Citations

0

Downloads

68

Views